This is a Validated Antibody Database (VAD) review about human HER2, based on 229 published articles (read how Labome selects the articles), using HER2 antibody in all methods. It is aimed to help Labome visitors find the most suited HER2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
HER2 synonym: CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1

Knockout validation
Cell Signaling Technology
domestic rabbit monoclonal (29D8)
  • western blot knockout validation; human; 1:200; fig 1a
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot knockout validation on human samples at 1:200 (fig 1a). Cancers (Basel) (2021) ncbi
Invitrogen
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; 1:1000; loading ...; fig 5s2a
Invitrogen HER2 antibody (ThermoFisher, MA5-14057) was used in western blot on human samples at 1:1000 (fig 5s2a). elife (2020) ncbi
domestic rabbit monoclonal (K.929.9)
  • other; human; 1:100; loading ...; fig 1b, 1s1a
Invitrogen HER2 antibody (Thermo Fisher, MA5-15050) was used in other on human samples at 1:100 (fig 1b, 1s1a). elife (2020) ncbi
mouse monoclonal (2G11)
  • other; human; 1:100; loading ...; fig 4c
Invitrogen HER2 antibody (Thermo Fisher, BMS120BT) was used in other on human samples at 1:100 (fig 4c). elife (2020) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunocytochemistry; human; 1:200; loading ...; fig 4a
  • western blot; human; 1:500; loading ...; fig 1
Invitrogen HER2 antibody (Thermo Fisher, MA5-14057) was used in immunocytochemistry on human samples at 1:200 (fig 4a) and in western blot on human samples at 1:500 (fig 1). Biomolecules (2020) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; loading ...; fig 1a
Invitrogen HER2 antibody (Thermo Scientific, MA5-14057) was used in western blot on human samples (fig 1a). Nat Commun (2019) ncbi
mouse monoclonal (e2-4001)
  • other; human; loading ...; fig 4c
Invitrogen HER2 antibody (Lab Vision, MS-325-P1) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2a
Invitrogen HER2 antibody (Thermo Fisher Scientific, RM-9103-S1) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2a). Cell (2018) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; loading ...; fig 3d
In order to develop a microfluidic immunostaining system for the standardization of immunohistochemical assays, Invitrogen HER2 antibody (Thermo Fisher, PA5-16305) was used in immunohistochemistry - paraffin section on human samples (fig 3d). Sci Rep (2017) ncbi
mouse monoclonal (e2-4001)
  • western blot; human; 1:10; loading ...; fig 2a
In order to describe a microfluidic western blot for an eight-plex protein panel for individual circulating tumor cells derived from estrogen receptor-positive breast cancer patients, Invitrogen HER2 antibody (Pierce, MA513105) was used in western blot on human samples at 1:10 (fig 2a). Nat Commun (2017) ncbi
mouse monoclonal (e2-4001)
  • reverse phase protein lysate microarray; human; loading ...; fig 7a
In order to characterize the molecular identity of uterine carcinosarcomas., Invitrogen HER2 antibody (Lab Vision, MS-325-P1) was used in reverse phase protein lysate microarray on human samples (fig 7a). Cancer Cell (2017) ncbi
mouse monoclonal (e2-4001)
  • reverse phase protein lysate microarray; human; loading ...; fig 3a
In order to describe the features of 228 primary cervical cancers, Invitrogen HER2 antibody (Lab Vision, MS-325-P1) was used in reverse phase protein lysate microarray on human samples (fig 3a). Nature (2017) ncbi
mouse monoclonal (e2-4001)
  • western blot; human; loading ...
In order to analyze the context specificity of signaling networks within a causal conceptual framework using reverse-phase protein array time-course assays and network analysis approaches, Invitrogen HER2 antibody (Lab Vision, MS-325-P1) was used in western blot on human samples . Cell Syst (2017) ncbi
domestic rabbit monoclonal (K.929.9)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 1b
In order to determine if PIK3CA mutations contribute to tumor initiation, Invitrogen HER2 antibody (Thermo Scientific, MA5-15050) was used in immunohistochemistry - paraffin section on mouse samples (fig 1b). Oncogenesis (2016) ncbi
mouse monoclonal (9G6.10)
  • immunohistochemistry; human; fig 3a
In order to perform Raman-encoded molecular imaging with five nanoparticle flavors, Invitrogen HER2 antibody (Thermo Scientific, MS-229-PABX) was used in immunohistochemistry on human samples (fig 3a). PLoS ONE (2016) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1c
In order to optimize in vivo and ex vivo fluorescence imaging for the preclinical development and characterization of therapeutic monoclonal antibodies, Invitrogen HER2 antibody (Thermo Fisher Scientific, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1c). MAbs (2017) ncbi
mouse monoclonal (N12)
  • immunocytochemistry; human; 1:100; fig s8
  • western blot; human; 1:100; fig s8
  • immunocytochemistry; mouse; 1:100; fig s7
  • western blot; mouse; 1:100; fig s7
In order to describe the role of Anks1a in COPII-mediated EphA2 export from the endoplasmic reticulum, Invitrogen HER2 antibody (Neomarkers, MA5-12998) was used in immunocytochemistry on human samples at 1:100 (fig s8), in western blot on human samples at 1:100 (fig s8), in immunocytochemistry on mouse samples at 1:100 (fig s7) and in western blot on mouse samples at 1:100 (fig s7). Nat Commun (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunocytochemistry; human; loading ...; fig 1b
  • immunohistochemistry; human; loading ...; fig 2a
In order to assess the use of HER2-HER3 dimerization as a biomarker for breast cancer, Invitrogen HER2 antibody (ThermoScientific, e2-4001+3B5) was used in immunocytochemistry on human samples (fig 1b) and in immunohistochemistry on human samples (fig 2a). Oncotarget (2016) ncbi
mouse monoclonal (PN2A)
  • western blot; human; 1:500; loading ...; fig 2d
In order to identify a role for S100P in the development of trastuzumab-resistance, Invitrogen HER2 antibody (Fisher, MS-1072-P0) was used in western blot on human samples at 1:500 (fig 2d). Oncotarget (2016) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 5
In order to classify triple-negative breast cancer into subtypes, Invitrogen HER2 antibody (Neomarkers, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 5). Oncol Lett (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry; human; loading ...
In order to investigate Bayesian methods for the analysis of exponential decay data, Invitrogen HER2 antibody (Thermo Fisher Scientific, e2-4001+3B5) was used in immunohistochemistry on human samples . PLoS ONE (2016) ncbi
mouse monoclonal (e2-4001)
  • western blot; human; loading ...; fig 5A
In order to develop a new affibody-drug conjugate against HER2-positive cell lines., Invitrogen HER2 antibody (Thermo Scientific Pierce Antibodies, e2-4001) was used in western blot on human samples (fig 5A). J Immunother (2016) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; tbl 1
In order to examine the association between pretreatment molecular and clinical factors and axillary lymph node metastases in early breast cancer, Invitrogen HER2 antibody (Thermo, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1). Medicine (Baltimore) (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; 1:2000; loading ...
In order to identify genetic features regulating cell survival after exposure to radiation., Invitrogen HER2 antibody (Thermo Fisher, MS730P0) was used in western blot on human samples at 1:2000. Nat Commun (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunoprecipitation; human; fig 2b
  • immunocytochemistry; human; 1:100; fig 3b
  • western blot; human; 1:1000; fig 1
In order to test if septins contribute to cancer by stabilizing ErbB2, Invitrogen HER2 antibody (Thermo Fisher Scientific, Ab-17) was used in immunoprecipitation on human samples (fig 2b), in immunocytochemistry on human samples at 1:100 (fig 3b) and in western blot on human samples at 1:1000 (fig 1). Biochem J (2016) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry; human; 1:200; loading ...
In order to explore the relationship between tumor-infiltrating lymphocytes and the clinical outcomes of triple-negative breast cancers, Invitrogen HER2 antibody (Thermoscientific, SP3) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2016) ncbi
mouse monoclonal (2G11)
  • flow cytometry; human; fig 5
In order to determine how hepatitis C virus activates a neuregulin-driven circuit to modify surface expression of growth factor receptors of the ErbB family, Invitrogen HER2 antibody (eBioscience, BMS120FI) was used in flow cytometry on human samples (fig 5). PLoS ONE (2016) ncbi
mouse monoclonal (9G6.10)
  • flow cytometry; human; fig 5
In order to learn about intraoperative guidance of breast cancer lumpectomy by quantitative molecular phenotyping with topically applied SERS nanoparticles, Invitrogen HER2 antibody (Thermo Scientific, MS-229-PABX) was used in flow cytometry on human samples (fig 5). Sci Rep (2016) ncbi
mouse monoclonal (e2-4001)
  • immunohistochemistry - paraffin section; human; 1:1000; fig 2
In order to determine the mechanisms of resistance to the pan-HER family inhibitor AZD8931, Invitrogen HER2 antibody (Invitrogen, AHO1011) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (fig 2). Dis Model Mech (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human; 1:400; tbl 4
In order to assess non-small cell lung cancers using a breast cancer-risk predictor gene signature, Invitrogen HER2 antibody (Thermo Scientific, MS-730) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 4). Neoplasia (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
In order to elucidate the role of Runx2 during the early stages of breast cancer and metastasis, Invitrogen HER2 antibody (Thermo Scientific, e2-4001 + 3B5) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Pathol Oncol Res (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; fig 3
In order to characterize distinct binding preferences for constitutive and stress-induced HSP90 isoforms and conformationally restricted mutants in regards to client proteins and small molecule inhibitors, Invitrogen HER2 antibody (Thermo Scientific, MS-730-P1) was used in western blot on human samples (fig 3). PLoS ONE (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; 1:1000; fig 2
In order to discuss how to improve treatment of pancreatic ductal adenocarcinomas with trastuzumab emtansine, Invitrogen HER2 antibody (Thermo Fisher Scientific, e2-4001 + 3B5) was used in western blot on human samples at 1:1000 (fig 2). BMC Cancer (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry; human; ready to use
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen HER2 antibody (Thermo Scientific, RM-9103-R7) was used in immunohistochemistry on human samples at ready to use. Pathol Res Pract (2015) ncbi
domestic rabbit monoclonal (EP1045Y)
  • immunohistochemistry; human; ready to use
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen HER2 antibody (Thermo Scientific, RM-2111-R7) was used in immunohistochemistry on human samples at ready to use. Pathol Res Pract (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1f
In order to develop a non-cross-reactive multiplex to measure 8 common breast cancer biomarkers, Invitrogen HER2 antibody (Thermo Fisher, MA5-14509) was used in immunohistochemistry - paraffin section on human samples (fig 1f). Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunocytochemistry; human; fig 3
In order to study breast cancer cell lines and chemomodulatory effects of didox and resveratrol on herceptin cytotoxicity, Invitrogen HER2 antibody (Thermo Scientific, MS-730-PCS) was used in immunocytochemistry on human samples (fig 3). Sci Rep (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 2
In order to characterize triple-negative breast cancer and the role of epithelial-mesenchymal transition markers, Invitrogen HER2 antibody (Thermo Lab Vision, RM-9103-S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 2). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (PN2A)
  • western blot; human; 1:200; fig 1
In order to study anti-tumor activity of breast cancer models resistant to anti-HER2 drugs due to a dual fatty acid synthase and HER2 signaling blockade, Invitrogen HER2 antibody (Thermo Scientific, MS-1072-P1) was used in western blot on human samples at 1:200 (fig 1). PLoS ONE (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:200
In order to assess the clinicopathological and immunohistochemical characteristics, and the clinical outcomes, between screen-detected and symptomatic DCIS, Invitrogen HER2 antibody (Thermo Scientific Lab Vision, RM-9103-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunoprecipitation; human; 1 ug/time
In order to characterize nine mutations in the receptor tyrosine kinase ERBB4 identified in lung adenocarcinoma, Invitrogen HER2 antibody (Thermo Scientific, MA5-14057) was used in immunoprecipitation on human samples at 1 ug/time. Oncogene (2016) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry; human; 1:100
Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry on human samples at 1:100. Breast (2015) ncbi
mouse monoclonal (e2-4001)
  • immunohistochemistry; human; 1:200
In order to evaluate expression of receptor tyrosine kinases, their ligands, and mutational status and correlate with features observed in solitary fibrous tumors, Invitrogen HER2 antibody (Lab vision, MS-325-PO) was used in immunohistochemistry on human samples at 1:200. Hum Pathol (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; 1:1000; fig 2b
In order to report that gemcitabine treatment increases HER2 expression by low HER2-expressing breast cancer cells, Invitrogen HER2 antibody (Thermo Fisher Scientific, e2-4001 + 3B5) was used in western blot on human samples at 1:1000 (fig 2b). Oncol Rep (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human
In order to discuss how to treat the four types of breast cancer, Invitrogen HER2 antibody (Thermo Scientific Lab Vision, SP3) was used in immunohistochemistry - paraffin section on human samples . Niger J Clin Pract (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human; 1:500
Invitrogen HER2 antibody (Thermo Scientific, e2-4001-3B5) was used in immunohistochemistry - paraffin section on human samples at 1:500. Turk J Gastroenterol (2014) ncbi
mouse monoclonal (e2-4001)
  • immunohistochemistry - paraffin section; human; fig 2
In order to characterize human solid salivary adenoid cystic carcinoma and high frequency of loss of PTEN expression as a targeted therapy, Invitrogen HER2 antibody (Thermo Scientific, MS325B0) was used in immunohistochemistry - paraffin section on human samples (fig 2). Oncotarget (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human; 1:100
Invitrogen HER2 antibody (Lab Vision, e2-4001+ 3B5) was used in immunohistochemistry - paraffin section on human samples at 1:100. World J Urol (2015) ncbi
mouse monoclonal (3B5)
  • immunohistochemistry; human
In order to determine the best method to assess HER2 status in breast cancer samples, Invitrogen HER2 antibody (LabVision, Ab15) was used in immunohistochemistry on human samples . Breast Cancer Res (2015) ncbi
mouse monoclonal (e2-4001)
  • immunohistochemistry; human
In order to determine the best method to assess HER2 status in breast cancer samples, Invitrogen HER2 antibody (LabVision, Ab8) was used in immunohistochemistry on human samples . Breast Cancer Res (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; tbl 2
In order to analyze breast cancer subtypes and retrospective analysis of metastatic behaviour, Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry - paraffin section on human samples (tbl 2). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human
In order to determine the rate of human epidermal growth factor receptor-2 discordance and its effect on treatment decisions in patients with advanced gastric cancer, Invitrogen HER2 antibody (Thermo, e2 4001+3B5) was used in immunohistochemistry - paraffin section on human samples . Jpn J Clin Oncol (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry; human; 1:200
In order to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma, Invitrogen HER2 antibody (Neomarker, RM-9103-R7) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (e2-4001)
  • immunoprecipitation; human; fig 3D
  • western blot; human; fig 3D
In order to elucidate the dimerization of ErbB2, Invitrogen HER2 antibody (Neomarkers, Ab8) was used in immunoprecipitation on human samples (fig 3D) and in western blot on human samples (fig 3D). Oncotarget (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunoprecipitation; human; fig 3D
  • western blot; human; fig 3D
In order to elucidate the dimerization of ErbB2, Invitrogen HER2 antibody (Neomarkers, Ab8) was used in immunoprecipitation on human samples (fig 3D) and in western blot on human samples (fig 3D). Oncotarget (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human
Invitrogen HER2 antibody (Lab Vision Corporation, SP3) was used in immunohistochemistry - paraffin section on human samples . Exp Ther Med (2015) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry; human; 1:100
Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry on human samples at 1:100. BMC Womens Health (2014) ncbi
mouse monoclonal (9G6.10)
  • western blot; human
Invitrogen HER2 antibody (Thermo Scientific, 9G6.10) was used in western blot on human samples . J Biol Chem (2014) ncbi
mouse monoclonal (e2-4001)
  • immunoprecipitation; human
  • western blot; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Invitrogen HER2 antibody (NeoMarkers, e2-4001) was used in immunoprecipitation on human samples and in western blot on human samples . Oncogene (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
In order to study the role of flotillin in the oncogenic effect of ErbB, Invitrogen HER2 antibody (Thermo Fisher Scientific, Ab-17) was used . Biochim Biophys Acta (2014) ncbi
mouse monoclonal (e2-4001)
  • immunohistochemistry - paraffin section; human; 1:300
Invitrogen HER2 antibody (LabVision, e2-4001) was used in immunohistochemistry - paraffin section on human samples at 1:300. Head Neck (2015) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry - paraffin section; human
In order to investigate the expression and activity of receptor tyrosine kinases, MAP kinase, AKT, or Hippo pathways in human schwannomas, Invitrogen HER2 antibody (LabVision, Ab-17) was used in immunohistochemistry - paraffin section on human samples . Neuro Oncol (2014) ncbi
mouse monoclonal (PN2A)
  • immunohistochemistry - paraffin section; human
In order to establish a tissue quality index as an intrinsic control for measurement of different effects of preanalytical variables on FFPE tissue, Invitrogen HER2 antibody (Thermo, PN2A) was used in immunohistochemistry - paraffin section on human samples . Lab Invest (2014) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:200
In order to study non-natural amino acid antibody drug conjugates, Invitrogen HER2 antibody (Thermo, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:200. PLoS ONE (2014) ncbi
mouse monoclonal (e2-4001, 3B5)
In order to study the role of neuregulin-1/glial growth factor in Schwann cell migration and its mechanism, Invitrogen HER2 antibody (Thermo Scientific, Ab-17) was used . Genes Cells (2014) ncbi
domestic rabbit monoclonal (EP1045Y)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 2
In order to report the clinicopathological features of 9 breast malignant fibrous histiocytoma patients, Invitrogen HER2 antibody (Lab Vision, EP1045Y) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 2). Sci Rep (2013) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
In order to review the contribution of Yes Associated Protein to various types of cancer, Invitrogen HER2 antibody (Neomarkers, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). Cell Oncol (Dordr) (2013) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1
In order to learn about a new potential marker for low risk of invasion in ductal carcinoma in situ is called basal cytokeratin, Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1). Clinics (Sao Paulo) (2013) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunohistochemistry; mouse; 1:1000
In order to study targeting sEcad for treatment of breast cancer, Invitrogen HER2 antibody (Thermo Fisher Scientific, Ab-17) was used in immunohistochemistry on mouse samples at 1:1000. Mol Carcinog (2014) ncbi
mouse monoclonal (e2-4001)
  • immunocytochemistry; human; fig 3
  • western blot; human; fig 1
In order to investigate factors that regulate ErbB2-ErbB3 heterodimerization, Invitrogen HER2 antibody (Thermo, Ab-8 (clone e2-4001)) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 1). Carcinogenesis (2013) ncbi
mouse monoclonal (e2-4001, 3B5)
In order to study the role of HER2/neu in vasculogenic mimicry in invasive breast carcinoma, Invitrogen HER2 antibody (Thermo SCIENTIFIC, MS-730-P0) was used . J Cell Mol Med (2013) ncbi
mouse monoclonal (e2-4001)
  • flow cytometry; human; fig 5
In order to study the influence of oncogene expression on cellular lipid profile, Invitrogen HER2 antibody (Biosource, AHO1011) was used in flow cytometry on human samples (fig 5). Biochim Biophys Acta (2012) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:200
In order to study EGFR gene in triple negative breast cancer and its therapeutic application, Invitrogen HER2 antibody (Neomarker, RM9103-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res (2011) ncbi
mouse monoclonal (3B5)
  • immunoprecipitation; human; loading ...; fig 7d
  • western blot; human; loading ...; fig 6a
In order to demonstrate that the beta4-dependent signaling in human squamous carcinoma cells is dependent on the syndecan family of matrix receptors, Invitrogen HER2 antibody (Fisher, 3B5) was used in immunoprecipitation on human samples (fig 7d) and in western blot on human samples (fig 6a). J Biol Chem (2010) ncbi
domestic rabbit recombinant (SP3)
  • immunohistochemistry - paraffin section; human; 1:400; tbl 3
  • immunohistochemistry; human; 1:400
In order to study the role of CLDN2 expression in breast cancer development and progression, Invitrogen HER2 antibody (NeoMarkers, SP3) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 3) and in immunohistochemistry on human samples at 1:400. Histopathology (2008) ncbi
mouse monoclonal (e2-4001, 3B5)
  • immunoprecipitation; human
  • western blot; human
In order to examine the role of E-cadherin and ADAM15 in ErbB receptor signaling, Invitrogen HER2 antibody (Lab Vision, e2-4001 + 3B5) was used in immunoprecipitation on human samples and in western blot on human samples . J Biol Chem (2008) ncbi
mouse monoclonal (e2-4001, 3B5)
  • western blot; human; 1:3000; fig 7
In order to investigate ErbB2 internalization, Invitrogen HER2 antibody (Neomarkers, Ab-17) was used in western blot on human samples at 1:3000 (fig 7). J Cell Sci (2006) ncbi
mouse monoclonal (9G6.10)
  • ELISA; human; tbl 2
In order to suggest that AEE788 is an anticancer agent that deregulates tumor cell proliferation and angiogenic parameters, Invitrogen HER2 antibody (NeoMarkers, MS229-PABX) was used in ELISA on human samples (tbl 2). Cancer Res (2004) ncbi
Santa Cruz Biotechnology
mouse monoclonal (3B5)
  • immunohistochemistry; mouse; 1:50; loading ...; fig 4b
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, 3B5) was used in immunohistochemistry on mouse samples at 1:50 (fig 4b). BMC Dev Biol (2021) ncbi
mouse monoclonal
  • immunohistochemistry; mouse; 1:50; loading ...; fig 4b
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, 3B5) was used in immunohistochemistry on mouse samples at 1:50 (fig 4b). BMC Dev Biol (2021) ncbi
mouse monoclonal (3B5)
  • western blot; human; loading ...; fig 4g
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-33684) was used in western blot on human samples (fig 4g). Theranostics (2021) ncbi
mouse monoclonal (3B5)
  • flow cytometry; human; loading ...; fig s4b
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-33684) was used in flow cytometry on human samples (fig s4b). MBio (2017) ncbi
mouse monoclonal (3B5)
  • ChIP-Seq; mouse; fig s3a
  • chromatin immunoprecipitation; mouse; fig s3b
  • ChIP-Seq; human; loading ...; fig s3c
  • chromatin immunoprecipitation; human; fig s3e
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, 3B5) was used in ChIP-Seq on mouse samples (fig s3a), in chromatin immunoprecipitation on mouse samples (fig s3b), in ChIP-Seq on human samples (fig s3c) and in chromatin immunoprecipitation on human samples (fig s3e). PLoS Genet (2017) ncbi
mouse monoclonal
  • ChIP-Seq; mouse; fig s3a
  • chromatin immunoprecipitation; mouse; fig s3b
  • ChIP-Seq; human; loading ...; fig s3c
  • chromatin immunoprecipitation; human; fig s3e
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, 3B5) was used in ChIP-Seq on mouse samples (fig s3a), in chromatin immunoprecipitation on mouse samples (fig s3b), in ChIP-Seq on human samples (fig s3c) and in chromatin immunoprecipitation on human samples (fig s3e). PLoS Genet (2017) ncbi
mouse monoclonal (9G6)
  • western blot; human; 1:500; loading ...; fig 5d
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-08) was used in western blot on human samples at 1:500 (fig 5d). Sci Rep (2017) ncbi
mouse monoclonal (3B5)
  • western blot; human; 1:1000; fig 2
In order to assess the role of Nrg1 signaling to Alzheimer's disease pathogenesis, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-33684) was used in western blot on human samples at 1:1000 (fig 2). Mol Med Rep (2016) ncbi
mouse monoclonal (19G5)
  • western blot; human; loading ...; fig 5c
In order to determine the effect of a mixture of two monoclonal antibodies against non-overlapping epitopes of HER2 on HER2 stability and localization, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, 19G5) was used in western blot on human samples (fig 5c). J Cell Mol Med (2016) ncbi
mouse monoclonal (3B5)
  • western blot; mouse; 1:500; fig 2
In order to study the alterations of brain Neuregulin-1 signaling during neuroinflammation, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-33684) was used in western blot on mouse samples at 1:500 (fig 2). Mol Med Rep (2016) ncbi
mouse monoclonal (7F8)
  • western blot; mouse; 1:500; fig 2
In order to study the alterations of brain Neuregulin-1 signaling during neuroinflammation, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-81508) was used in western blot on mouse samples at 1:500 (fig 2). Mol Med Rep (2016) ncbi
mouse monoclonal (F-11)
  • immunoprecipitation; human; fig 1
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-7301) was used in immunoprecipitation on human samples (fig 1). Oncogenesis (2016) ncbi
mouse monoclonal (24D2)
  • flow cytometry; mouse; fig 5
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, SC-23864) was used in flow cytometry on mouse samples (fig 5). Analyst (2015) ncbi
mouse monoclonal (3B5)
  • immunohistochemistry - paraffin section; human; tbl 3
Santa Cruz Biotechnology HER2 antibody (SantaCruz, sc-33684) was used in immunohistochemistry - paraffin section on human samples (tbl 3). Genes Cancer (2015) ncbi
mouse monoclonal (F-11)
  • western blot; human; fig 3A
In order to elucidate the dimerization of ErbB2, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-7301) was used in western blot on human samples (fig 3A). Oncotarget (2015) ncbi
mouse monoclonal (3B5)
  • western blot; human
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, sc-33684) was used in western blot on human samples . Int J Oncol (2014) ncbi
mouse monoclonal (9G6)
  • immunohistochemistry - paraffin section; human; 1:100
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-08) was used in immunohistochemistry - paraffin section on human samples at 1:100. J Biol Chem (2014) ncbi
Abcam
domestic rabbit monoclonal (EPR19547-12)
  • immunohistochemistry - paraffin section; human; 1:200; fig s1c
Abcam HER2 antibody (Abcam, ab214275) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig s1c). Sci Adv (2022) ncbi
domestic rabbit monoclonal (EP2324Y)
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig 9i
Abcam HER2 antibody (Abcam, ab237060) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 9i). J Clin Invest (2022) ncbi
domestic rabbit monoclonal (EPR19547-12)
  • immunohistochemistry; human; 1:1000; loading ...; fig s4
Abcam HER2 antibody (Abcam, ab214275) was used in immunohistochemistry on human samples at 1:1000 (fig s4). NPJ Breast Cancer (2021) ncbi
domestic rabbit monoclonal (EP1045Y)
  • western blot; human; 1:1000; loading ...; fig 7c
Abcam HER2 antibody (Abcam, ab134182) was used in western blot on human samples at 1:1000 (fig 7c). Theranostics (2020) ncbi
domestic rabbit monoclonal
  • other; human; 1:100; loading ...; fig 2d
Abcam HER2 antibody (Abcam, ab53290) was used in other on human samples at 1:100 (fig 2d). elife (2020) ncbi
domestic rabbit polyclonal
  • western blot; rat; 1:500; fig 5a
Abcam HER2 antibody (Abcam, ab47262) was used in western blot on rat samples at 1:500 (fig 5a). Biomed Res Int (2019) ncbi
mouse monoclonal (3B5)
  • immunohistochemistry; mouse; loading ...; fig 2g
Abcam HER2 antibody (Abcam, AB16901) was used in immunohistochemistry on mouse samples (fig 2g). Nature (2017) ncbi
domestic rabbit monoclonal (EP1045Y)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3d
In order to develop a microfluidic immunostaining system for the standardization of immunohistochemical assays, Abcam HER2 antibody (Abcam, ab134182) was used in immunohistochemistry - paraffin section on human samples (fig 3d). Sci Rep (2017) ncbi
mouse monoclonal (9G6)
Abcam HER2 antibody (abcam, ab16899) was used . PLoS ONE (2017) ncbi
domestic rabbit monoclonal (EP2324Y)
  • immunohistochemistry; mouse; 1:100; loading ...; fig 5a
Abcam HER2 antibody (Abcam, ab108371) was used in immunohistochemistry on mouse samples at 1:100 (fig 5a). J Clin Invest (2016) ncbi
domestic rabbit monoclonal (SP3)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2b
In order to investigate the interaction between breast cancer subtype and treatment using data from a breast cancer trial randomizing women to adjuvant chemotherapy, Abcam HER2 antibody (Abcam, SP3) was used in immunohistochemistry - paraffin section on human samples (fig 2b). Clin Cancer Res (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; fig 6
Abcam HER2 antibody (Abcam, ab47262) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Oncotarget (2016) ncbi
  • western blot; human; fig 1
Abcam HER2 antibody (Abcam, ab131104) was used in western blot on human samples (fig 1). Breast Cancer Res (2015) ncbi
BioLegend
mouse monoclonal (24D2)
  • flow cytometry; human
BioLegend HER2 antibody (BioLegend, 324404) was used in flow cytometry on human samples . Front Immunol (2022) ncbi
mouse monoclonal (24D2)
  • flow cytometry; human; 1:100; loading ...; fig s6d
BioLegend HER2 antibody (BioLegend, 324408) was used in flow cytometry on human samples at 1:100 (fig s6d). J Immunother Cancer (2022) ncbi
mouse monoclonal (24D2)
  • flow cytometry; human; loading ...; fig 2
BioLegend HER2 antibody (BioLegend, 324412) was used in flow cytometry on human samples (fig 2). Life (Basel) (2021) ncbi
mouse monoclonal (24D2)
  • western blot; human; 1:100; loading ...; fig ex7d
BioLegend HER2 antibody (BioLegend, cat324412) was used in western blot on human samples at 1:100 (fig ex7d). Nat Med (2019) ncbi
mouse monoclonal (24D2)
  • flow cytometry; mouse; 1:100; loading ...; fig 1m
BioLegend HER2 antibody (Biolegend, 324412) was used in flow cytometry on mouse samples at 1:100 (fig 1m). Nat Cell Biol (2019) ncbi
mouse monoclonal (24D2)
  • other; human; 500 ug/ml; fig 1
BioLegend HER2 antibody (BioLegend, 324402) was used in other on human samples at 500 ug/ml (fig 1). J Extracell Vesicles (2016) ncbi
mouse monoclonal (24D2)
BioLegend HER2 antibody (Biolegend, 324405) was used . Sci Rep (2015) ncbi
mouse monoclonal (24D2)
  • flow cytometry; human; fig 2
In order to discuss how to improve treatment of pancreatic ductal adenocarcinomas with trastuzumab emtansine, BioLegend HER2 antibody (BioLegend, 24D2) was used in flow cytometry on human samples (fig 2). BMC Cancer (2015) ncbi
mouse monoclonal (24D2)
  • flow cytometry; human; fig 4
In order to report that gemcitabine treatment increases HER2 expression by low HER2-expressing breast cancer cells, BioLegend HER2 antibody (BioLegend, 24D2) was used in flow cytometry on human samples (fig 4). Oncol Rep (2015) ncbi
R&D Systems
mouse monoclonal (191924)
  • flow cytometry; human; loading ...; fig s2c, s2d
R&D Systems HER2 antibody (R&D Catalog, FAB1129A) was used in flow cytometry on human samples (fig s2c, s2d). Nat Commun (2022) ncbi
domestic goat polyclonal
  • flow cytometry; human; 1:200; fig s4a
R&D Systems HER2 antibody (Biotechne, BAF1129) was used in flow cytometry on human samples at 1:200 (fig s4a). Cancer Res (2021) ncbi
OriGene
mouse monoclonal (UMAB36)
  • western blot; human; 1:2000; loading ...; fig 1c
OriGene HER2 antibody (OriGene Technologies, UMAB36) was used in western blot on human samples at 1:2000 (fig 1c). Biochem Biophys Res Commun (2017) ncbi
mouse monoclonal (OTI4F10)
  • western blot; human; 1:1000; fig s8
In order to investigate the role of channel gating in mammalian proteasomes, OriGene HER2 antibody (OriGene, TA503443) was used in western blot on human samples at 1:1000 (fig s8). Nat Commun (2016) ncbi
Novus Biologicals
domestic rabbit polyclonal (MT1/410)
  • immunohistochemistry; mouse; loading ...; fig 6a
Novus Biologicals HER2 antibody (Novus Biologicals, NBP1-84584) was used in immunohistochemistry on mouse samples (fig 6a). Cell Mol Gastroenterol Hepatol (2019) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D8F12)
  • western blot; human; 1:1000; fig 1f
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig s5a
Cell Signaling Technology HER2 antibody (CST, 8609) was used in western blot on human samples at 1:1000 (fig 1f) and in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig s5a). Allergy Asthma Immunol Res (2022) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; 1:1000; fig 4a
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290S) was used in western blot on human samples at 1:1000 (fig 4a). Nature (2022) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 6a, 6b, 6c, 6d
Cell Signaling Technology HER2 antibody (CST, 4290) was used in western blot on human samples (fig 6a, 6b, 6c, 6d). Cell Oncol (Dordr) (2022) ncbi
domestic rabbit monoclonal (D66B7)
  • western blot; human; loading ...; fig 6a, 6b, 6c, 6d
Cell Signaling Technology HER2 antibody (CST, 6942) was used in western blot on human samples (fig 6a, 6b, 6c, 6d). Cell Oncol (Dordr) (2022) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 2a
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in immunohistochemistry - paraffin section on mouse samples (fig 2a). Cancers (Basel) (2022) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry; mouse; 1:500
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry on mouse samples at 1:500. Nat Commun (2022) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290S) was used in western blot on human samples (fig 3a). Thorac Cancer (2022) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243T) was used in western blot on human samples (fig 3a). Thorac Cancer (2022) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 4
Cell Signaling Technology HER2 antibody (CST, 2242) was used in western blot on human samples (fig 4). Cancers (Basel) (2022) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4b
Cell Signaling Technology HER2 antibody (CST, 2165) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4b). Nat Cancer (2022) ncbi
domestic rabbit monoclonal (29D8)
  • immunoprecipitation; mouse; 1:100; loading ...; fig 11
  • western blot; mouse; 1:1000; loading ...; fig 9e
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunoprecipitation on mouse samples at 1:100 (fig 11) and in western blot on mouse samples at 1:1000 (fig 9e). J Clin Invest (2022) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; mouse; 1:1000; loading ...; fig 9e
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on mouse samples at 1:1000 (fig 9e). J Clin Invest (2022) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:1000; loading ...; fig 3b, s4c
  • western blot; mouse; 1:1000; loading ...; fig 3a
Cell Signaling Technology HER2 antibody (Cell signaling, 29D8) was used in western blot on human samples at 1:1000 (fig 3b, s4c) and in western blot on mouse samples at 1:1000 (fig 3a). Proc Natl Acad Sci U S A (2021) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; 1:1000; loading ...; fig s1a
Cell Signaling Technology HER2 antibody (CST, 4290) was used in western blot on human samples at 1:1000 (fig s1a). NPJ Breast Cancer (2021) ncbi
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 4b
Cell Signaling Technology HER2 antibody (CST, 3250s) was used in western blot on mouse samples (fig 4b). J Cell Mol Med (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry; human; 1:50; loading ...
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2242S) was used in immunohistochemistry on human samples at 1:50. BMC Cancer (2021) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 6a
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples (fig 6a). J Exp Clin Cancer Res (2021) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; fig 1c
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples (fig 1c). Am J Cancer Res (2021) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; mouse; 1:1000; fig 3c, 3e, 3f
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 4290) was used in western blot on mouse samples at 1:1000 (fig 3c, 3e, 3f). Arterioscler Thromb Vasc Biol (2021) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry; mouse; 1:500; loading ...; fig 1g
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry on mouse samples at 1:500 (fig 1g). Oncogene (2021) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human; loading ...; fig 2b
  • western blot; human; loading ...; fig 2c
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in immunocytochemistry on human samples (fig 2b) and in western blot on human samples (fig 2c). Theranostics (2021) ncbi
domestic rabbit monoclonal (29D8)
  • western blot knockout validation; human; 1:200; fig 1a
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot knockout validation on human samples at 1:200 (fig 1a). Cancers (Basel) (2021) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; mouse; loading ...
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on mouse samples . Cell Rep (2021) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry; mouse; loading ...; fig s2a
  • western blot; mouse; loading ...; fig s2b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry on mouse samples (fig s2a) and in western blot on mouse samples (fig s2b). Cell Rep (2021) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 1c
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 1c). Nat Commun (2021) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig s2f
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig s2f). Mol Oncol (2021) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:1000; loading ...; fig 4a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2241) was used in western blot on mouse samples at 1:1000 (fig 4a). Cancer Sci (2021) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; mouse; 1:1000; loading ...; fig 4a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on mouse samples at 1:1000 (fig 4a). Cancer Sci (2021) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; mouse; 1:1000; loading ...; fig 8b
Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in western blot on mouse samples at 1:1000 (fig 8b). J Clin Invest (2021) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 3a). Cancer Res (2021) ncbi
domestic rabbit monoclonal (6B12)
  • other; human; 1:100; loading ...; fig 2d
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243S) was used in other on human samples at 1:100 (fig 2d). elife (2020) ncbi
domestic rabbit monoclonal (D66B7)
  • other; human; 1:100; loading ...; fig 2d
Cell Signaling Technology HER2 antibody (Cell Signaling, 6942S) was used in other on human samples at 1:100 (fig 2d). elife (2020) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). BMC Cancer (2020) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 1b, 2b
Cell Signaling Technology HER2 antibody (CST, 29D8) was used in western blot on human samples (fig 1b, 2b). EBioMedicine (2020) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:1000; loading ...; fig s1d
Cell Signaling Technology HER2 antibody (Cell Signaling, 2242) was used in western blot on mouse samples at 1:1000 (fig s1d). Nat Commun (2019) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology HER2 antibody (CST, 2165) was used in western blot on human samples (fig 1a). Cell Commun Signal (2019) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:1000; loading ...; fig 3d
Cell Signaling Technology HER2 antibody (Cell Signalling Technology, 2241) was used in western blot on mouse samples at 1:1000 (fig 3d). Breast Cancer Res (2019) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; 1:1000; loading ...; fig 3c, 3d, s8b
Cell Signaling Technology HER2 antibody (CST, 2243S) was used in western blot on human samples at 1:1000 (fig 3c, 3d, s8b). Science (2019) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 5f
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 5f). Breast Cancer Res (2019) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; mouse; loading ...; fig 4c
Cell Signaling Technology HER2 antibody (Cell Signalling, D8F12) was used in western blot on mouse samples (fig 4c). Nutrients (2019) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig s2
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples (fig s2). Breast Cancer Res (2019) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig s3b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig s3b). Oncogene (2019) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig s3b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig s3b). Oncogene (2019) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 5e
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples (fig 5e). Cell Res (2018) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 5e
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 5e). Cell Res (2018) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry - paraffin section; human; 1:100; fig 6c
Cell Signaling Technology HER2 antibody (CST, 4290) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6c). Nat Commun (2018) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; 1:1000; loading ...; fig 1e
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples at 1:1000 (fig 1e). Science (2018) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 2b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 2b). Oncotarget (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 2b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2247) was used in western blot on human samples (fig 2b). Oncotarget (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 1c
Cell Signaling Technology HER2 antibody (Cell Signaling, 2242) was used in western blot on human samples (fig 1c). Oncotarget (2017) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:1000; loading ...; fig 3c
Cell Signaling Technology HER2 antibody (cell signaling, 2249) was used in western blot on mouse samples at 1:1000 (fig 3c). Oncogene (2017) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; mouse; 1:1000; loading ...; fig 1g
In order to observe a novel role for ErbB4 in macrophage apoptosis, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on mouse samples at 1:1000 (fig 1g). Cell Death Dis (2017) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry; human; 1:500; fig 7b
  • western blot; human; loading ...; fig 3c
In order to report that lactate dehydrogenase A phosphorylation results in pro-invasive, anti-anoikis, and pro-metastatic advantages to cancer cells, Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 4290) was used in immunohistochemistry on human samples at 1:500 (fig 7b) and in western blot on human samples (fig 3c). Oncogene (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 3c
In order to report that lactate dehydrogenase A phosphorylation results in pro-invasive, anti-anoikis, and pro-metastatic advantages to cancer cells, Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2247) was used in western blot on human samples (fig 3c). Oncogene (2017) ncbi
domestic rabbit monoclonal (D66B7)
  • western blot; human; loading ...; fig 5a
In order to discover regions of rare genetic variation that contribute to emphysema with severe airflow obstruction, Cell Signaling Technology HER2 antibody (Cell Signaling, 6942) was used in western blot on human samples (fig 5a). Am J Respir Crit Care Med (2017) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 5a
In order to discover regions of rare genetic variation that contribute to emphysema with severe airflow obstruction, Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in western blot on human samples (fig 5a). Am J Respir Crit Care Med (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig s6
Cell Signaling Technology HER2 antibody (Cell Signaling, 2241) was used in western blot on human samples (fig s6). Sci Rep (2016) ncbi
domestic rabbit monoclonal (D8F12)
  • immunocytochemistry; human; 1:100; loading ...; fig 2b
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in immunocytochemistry on human samples at 1:100 (fig 2b) and in western blot on human samples (fig 2a). Sci Rep (2016) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig s6
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig s6). Sci Rep (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:1000; loading ...; fig 3
In order to assess the contribution of amphiregulin, epidermal growth factor, heparin-binding epidermal growth factor, and transforming growth factor alpha in the responsiveness of gastric cancer cell lines to cetuximab and trastuzumab, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples at 1:1000 (fig 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 3
In order to assess the contribution of amphiregulin, epidermal growth factor, heparin-binding epidermal growth factor, and transforming growth factor alpha in the responsiveness of gastric cancer cell lines to cetuximab and trastuzumab, Cell Signaling Technology HER2 antibody (Cell Signaling, 2247) was used in western blot on human samples at 1:1000 (fig 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 3a
In order to show that 2-hydroxyoleic acid treatment alters cell signaling and intracellular transport, Cell Signaling Technology HER2 antibody (Cell Signaling, 2241) was used in western blot on human samples (fig 3a). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:2000; loading ...; fig s6a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2242) was used in western blot on human samples at 1:2000 (fig s6a). Nat Cell Biol (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:1000; loading ...; fig 4g
In order to demonstrate the bipartite role of Hsp90 in chaperoning CRAF kinase, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165S) was used in western blot on human samples at 1:1000 (fig 4g). J Biol Chem (2016) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; 1:1000; loading ...; fig 4g
In order to demonstrate the bipartite role of Hsp90 in chaperoning CRAF kinase, Cell Signaling Technology HER2 antibody (Cell Signaling, 2243S) was used in western blot on human samples at 1:1000 (fig 4g). J Biol Chem (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:200; fig st1
In order to identify and characterize alterations in signal transduction that occur during the development Lapatinib resistance, Cell Signaling Technology HER2 antibody (Cell Signaling, 2241) was used in western blot on human samples at 1:200 (fig st1). Nat Commun (2016) ncbi
domestic rabbit monoclonal (29D8)
  • flow cytometry; human; loading ...; fig 1a
  • immunocytochemistry; human
  • immunohistochemistry; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 29D8) was used in flow cytometry on human samples (fig 1a), in immunocytochemistry on human samples and in immunohistochemistry on human samples . Nature (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 2a
In order to study how CUB domain-containing protein1 contributes to metastasis and drug resistance, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 2a). Breast Cancer Res (2016) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry - paraffin section; human; loading ...; tbl 1
Cell Signaling Technology HER2 antibody (Cell signaling, D8F12) was used in immunohistochemistry - paraffin section on human samples (tbl 1). Oncotarget (2016) ncbi
domestic rabbit monoclonal (29D8)
  • immunoprecipitation; human; loading ...; fig s8
In order to determine the effect of a mixture of two monoclonal antibodies against non-overlapping epitopes of HER2 on HER2 stability and localization, Cell Signaling Technology HER2 antibody (Cell signaling, 29D8) was used in immunoprecipitation on human samples (fig s8). J Cell Mol Med (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 2c
In order to identify a role for S100P in the development of trastuzumab-resistance, Cell Signaling Technology HER2 antibody (Cell Signaling, 2242S) was used in western blot on human samples at 1:1000 (fig 2c). Oncotarget (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 1a
In order to assess the importance of the IGF1R tyrosine kinase in triple-negative gastric cancer with and without oncogenic KRAS, BRAF or PI3K3CA mutations, Cell Signaling Technology HER2 antibody (Cell signaling, 2165) was used in western blot on human samples (fig 1a). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:500; fig s2
Cell Signaling Technology HER2 antibody (Cell Signaling, 2249) was used in western blot on human samples at 1:500 (fig s2). Nat Commun (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 3a
In order to investigate the interaction between MUC13 and HER2, Cell Signaling Technology HER2 antibody (Cell Signaling, 2247) was used in western blot on human samples (fig 3a). Oncogene (2017) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 4b
Cell Signaling Technology HER2 antibody (cell signalling, 2243) was used in western blot on human samples (fig 4b). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 4a
Cell Signaling Technology HER2 antibody (cell signalling, 2242) was used in western blot on human samples (fig 4a). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 5f
In order to identify genetic features regulating cell survival after exposure to radiation., Cell Signaling Technology HER2 antibody (Cell Signalling, 2247) was used in western blot on human samples at 1:1000 (fig 5f). Nat Commun (2016) ncbi
domestic rabbit monoclonal (29D8)
Cell Signaling Technology HER2 antibody (CST, 2165S) was used . Oncogenesis (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:500; fig 2
Cell Signaling Technology HER2 antibody (Cell signaling, 2165) was used in western blot on human samples at 1:500 (fig 2). elife (2016) ncbi
domestic rabbit monoclonal (D8F12)
  • immunohistochemistry - paraffin section; mouse; fig 6
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Oncotarget (2016) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; fig 1
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 1). Oncogenesis (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; fig 1b
In order to determine how hepatitis C virus activates a neuregulin-driven circuit to modify surface expression of growth factor receptors of the ErbB family, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 1b). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; fig 1
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot on human samples (fig 1). Oncogene (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 3b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2249) was used in western blot on human samples (fig 3b). Oncogene (2016) ncbi
domestic rabbit polyclonal
  • immunocytochemistry; human; loading ...; fig s2
  • western blot; human; loading ...; fig s3a
Cell Signaling Technology HER2 antibody (Cell Signaling, 2242) was used in immunocytochemistry on human samples (fig s2) and in western blot on human samples (fig s3a). Oncogene (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
In order to characterize colorectal cancer and nuclear localization of YBX1 and uncoupling of EGFR-RAS signaling, Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2242) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). Oncogenesis (2016) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human; fig 2
  • western blot; human; fig 2
Cell Signaling Technology HER2 antibody (Cell Signalling, 2165S) was used in immunocytochemistry on human samples (fig 2) and in western blot on human samples (fig 2). Oxid Med Cell Longev (2016) ncbi
domestic rabbit polyclonal
  • immunocytochemistry; mouse
  • western blot; human; fig 4
Cell Signaling Technology HER2 antibody (Cell Signalling, 2241S) was used in immunocytochemistry on mouse samples and in western blot on human samples (fig 4). Oxid Med Cell Longev (2016) ncbi
domestic rabbit monoclonal (6B12)
  • immunocytochemistry; human; fig 1
  • western blot; human; fig 1
In order to study the interactions between PMCA2 and HER2 in breast cancer cells, Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2243) was used in immunocytochemistry on human samples (fig 1) and in western blot on human samples (fig 1). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:200; loading ...; fig 2b
In order to demonstrate that receptor tyrosine kinase-like orphan receptor 1 is a scaffold for cavin-1 and caveolin-1, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples at 1:200 (fig 2b). Nat Commun (2016) ncbi
mouse monoclonal (44E7)
  • western blot; human; 1:1000
In order to determine the mechanisms of resistance to the pan-HER family inhibitor AZD8931, Cell Signaling Technology HER2 antibody (Cell Signaling, 2248) was used in western blot on human samples at 1:1000. Dis Model Mech (2016) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology HER2 antibody (Cell signaling, 2243) was used in western blot on human samples (fig 3a). Oncotarget (2016) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; dogs; 1:1000; fig 5
Cell Signaling Technology HER2 antibody (Cell Signaling, 4290S) was used in western blot on dogs samples at 1:1000 (fig 5). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:1000; fig 7e
In order to test if ado-trastuzumab emtansine overcomes trastuzumab resistance in murine models of brain metastases, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples at 1:1000 (fig 7e). J Natl Cancer Inst (2016) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; 1:1000; fig 7e
In order to test if ado-trastuzumab emtansine overcomes trastuzumab resistance in murine models of brain metastases, Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples at 1:1000 (fig 7e). J Natl Cancer Inst (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 5C; S6B
Cell Signaling Technology HER2 antibody (Cell Sgnaling, 2247) was used in western blot on human samples at 1:1000 (fig 5C; S6B). Mol Oncol (2016) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:1000; loading ...; fig 5C; S6B
Cell Signaling Technology HER2 antibody (Cell Sgnaling, 29D8) was used in western blot on human samples at 1:1000 (fig 5C; S6B). Mol Oncol (2016) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human; fig 4
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunocytochemistry on human samples (fig 4). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human; loading ...; fig 4a
Cell Signaling Technology HER2 antibody (Cell signaling, 4290) was used in western blot on human samples (fig 4a). J Biol Chem (2015) ncbi
domestic rabbit monoclonal (D66B7)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology HER2 antibody (Cell signaling, 6942) was used in western blot on human samples (fig 2a). J Biol Chem (2015) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1f
In order to develop a non-cross-reactive multiplex to measure 8 common breast cancer biomarkers, Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in immunohistochemistry - paraffin section on human samples (fig 1f). Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (44E7)
  • western blot; human; fig 5b
  • western blot; mouse; fig 5b
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2248) was used in western blot on human samples (fig 5b) and in western blot on mouse samples (fig 5b). Mol Ther (2015) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; mouse; fig 5b
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2243) was used in western blot on mouse samples (fig 5b). Mol Ther (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; fig 4
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 4). EBioMedicine (2015) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; fig 4
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 4). EBioMedicine (2015) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; fig 2
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
domestic rabbit monoclonal (29D8)
  • immunohistochemistry - paraffin section; human; 1:25
In order to develop and characterize patient-derived primary xenografts to a model of muscle invasive bladder cancer, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry - paraffin section on human samples at 1:25. Oncotarget (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; 1:100
In order to study the role of Tn expression and post-translationally modifications in pancreatic ductal adenocarcinoma, Cell Signaling Technology HER2 antibody (Cell Signaling, #2165) was used in western blot on human samples at 1:100. Mol Cancer (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; mouse; 1:1000; loading ...; fig 5b
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on mouse samples at 1:1000 (fig 5b). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 4f, 4g, 4h
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot on human samples (fig 4f, 4g, 4h). Oncotarget (2015) ncbi
domestic rabbit monoclonal (29D8)
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used . J Extracell Vesicles (2015) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; fig 3A
In order to elucidate the dimerization of ErbB2, Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 3A). Oncotarget (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot on human samples . J Diabetes (2016) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human; fig 3
  • western blot; human; fig 1
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 1). Breast Cancer Res (2015) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; fig s1
Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig s1). Oncogene (2015) ncbi
mouse monoclonal (44E7)
  • western blot; human; 1:1000; fig 2
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2248) was used in western blot on human samples at 1:1000 (fig 2). elife (2014) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human
In order to identify mechanisms by which metastatic gastroesophageal adenocarcinomas develop resistance to ERBB2 inhibition, Cell Signaling Technology HER2 antibody (Cell Signaling Technologies, 2165) was used in western blot on human samples . PLoS ONE (2014) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human
In order to identify mechanisms by which metastatic gastroesophageal adenocarcinomas develop resistance to ERBB2 inhibition, Cell Signaling Technology HER2 antibody (Cell Signaling Technologies, 2243) was used in western blot on human samples . PLoS ONE (2014) ncbi
domestic rabbit monoclonal (D8F12)
  • western blot; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 4290) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2243) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (D66B7)
  • western blot; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 6942) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Cell Signaling Technology HER2 antibody (cell signaling, 2243S) was used in western blot on human samples . Oncogene (2015) ncbi
mouse monoclonal (44E7)
  • western blot; human; 1:1000
Cell Signaling Technology HER2 antibody (Cell Signaling, 2248) was used in western blot on human samples at 1:1000. Front Endocrinol (Lausanne) (2014) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human
  • western blot; human
In order to study the role of flotillin in the oncogenic effect of ErbB, Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in immunocytochemistry on human samples and in western blot on human samples . Biochim Biophys Acta (2014) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology HER2 antibody (Cell signaling, 2165) was used in western blot on human samples (fig 1a). Int J Oncol (2014) ncbi
domestic rabbit monoclonal (29D8)
  • western blot; human; fig 2
In order to study targeting sEcad for treatment of breast cancer, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 2). Mol Carcinog (2014) ncbi
domestic rabbit monoclonal (6B12)
  • western blot; human; fig 2
In order to study targeting sEcad for treatment of breast cancer, Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 2). Mol Carcinog (2014) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; mouse; 1:200
  • western blot; mouse; 1:1000
Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in immunocytochemistry on mouse samples at 1:200 and in western blot on mouse samples at 1:1000. Dev Biol (2013) ncbi
domestic rabbit monoclonal (29D8)
  • immunocytochemistry; human; 1:150
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 29D8) was used in immunocytochemistry on human samples at 1:150. Breast Cancer Res (2011) ncbi
Dako
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 5a
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on mouse samples (fig 5a). Front Cell Dev Biol (2022) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:250; loading ...; fig s2a
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on mouse samples at 1:250 (fig s2a). Cancer Res (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1.6 ug/ml; loading ...; fig 3d
In order to develop a microfluidic immunostaining system for the standardization of immunohistochemical assays, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on human samples at 1.6 ug/ml (fig 3d). Sci Rep (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 3a
In order to compare HER2 and prolactin receptor trafficking, Dako HER2 antibody (DAKO, A0485) was used in western blot on human samples (fig 3a). Mol Cancer Ther (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 6c
In order to study the architecture of the mouse mammary gland using high-resolution 3D imaging, Dako HER2 antibody (DAKO, A0485) was used in immunohistochemistry - paraffin section on mouse samples (fig 6c). Breast Cancer Res (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig 1a
In order to suggest that EGFR promotes survival of prostate tumor-initiating cells and circulating tumor cells that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 1a). Cancer Res (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; rat; loading ...; fig 1
In order to investigate the contribution of PI3K/AKT pathway to the development of radiation carcinogenesis, Dako HER2 antibody (DAKO, A0485) was used in immunohistochemistry - paraffin section on rat samples (fig 1). J Radiat Res (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:200; fig st1
In order to identify and characterize alterations in signal transduction that occur during the development Lapatinib resistance, Dako HER2 antibody (Dako, A0485) was used in western blot on human samples at 1:200 (fig st1). Nat Commun (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig s1
In order to describe the effects of HER2 overexpression in breast cancer cells, Dako HER2 antibody (Dako, A0485) was used in western blot on human samples (fig s1). Nat Commun (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:250; loading ...; tbl 1
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on human samples at 1:250 (tbl 1). BMC Cancer (2016) ncbi
domestic rabbit polyclonal
  • immunoprecipitation; human; loading ...; fig 1b
  • immunocytochemistry; human; loading ...; fig 1a
  • western blot; human; loading ...; fig 1b
In order to investigate the interaction between MUC13 and HER2, Dako HER2 antibody (Dako, A0485) was used in immunoprecipitation on human samples (fig 1b), in immunocytochemistry on human samples (fig 1a) and in western blot on human samples (fig 1b). Oncogene (2017) ncbi
domestic rabbit polyclonal
  • western blot; dogs; 1:1000; fig 1a
In order to analyze the production of a synergistic effect on cancer cell proliferation and migration in vitro due to dual targeting of ERBB2 and EGFR pathways, Dako HER2 antibody (Dako, A0485) was used in western blot on dogs samples at 1:1000 (fig 1a). Vet Comp Oncol (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry; human; loading ...; fig 1
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry on human samples (fig 1). Mol Imaging Biol (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:400; fig s1
In order to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig s1). BMC Cancer (2016) ncbi
domestic rabbit polyclonal
  • western blot; cat; 1:3,500; fig 5b
In order to develop an assay to measure serum HER2 in order to diagnose cats with mammary carcinomas, Dako HER2 antibody (Dako, A0485) was used in western blot on cat samples at 1:3,500 (fig 5b). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; loading ...; tbl s2
In order to use microfluidic immunofluorescence staining to quantify HER2 gene copies, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on human samples (tbl s2). Sci Rep (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:500
In order to characterize aggressive tumors in African breast cancer and the strong expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) and its association with Axl expression, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry - paraffin section on human samples at 1:500. PLoS ONE (2016) ncbi
Ventana
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; mouse; loading ...
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on mouse samples . Cell Mol Gastroenterol Hepatol (2021) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3d
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (fig 3d). Sci Rep (2021) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry; human; 1:250; loading ...
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry on human samples at 1:250. Mod Pathol (2020) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1d
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (fig 1d). Sci Rep (2020) ncbi
domestic rabbit monoclonal (4B5)
  • immunocytochemistry; human; loading ...; fig 1c
Ventana HER2 antibody (Ventana, 4B5) was used in immunocytochemistry on human samples (fig 1c). Nat Commun (2019) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; loading ...; tbl s1
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (tbl s1). Am J Pathol (2017) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1g
  • western blot; human; 1:10; loading ...; fig 1c
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (fig 1g) and in western blot on human samples at 1:10 (fig 1c). Biochem Biophys Res Commun (2017) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; tbl 3
In order to characterize the spindle cell type of metaplastic breast carcinoma with myoepithelial features and report that this subtype exhibits a higher frequency of PIK3CA mutation than other types of metaplastic breast carcinoma, Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (tbl 3). Virchows Arch (2016) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry; human; loading ...
In order to report the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer, Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry on human samples . Gut Liver (2016) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry; human; loading ...
In order to report the demographic characteristics, recurrence pattern, and survival rate in Colombian females with breast cancer, Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry on human samples . Ecancermedicalscience (2015) ncbi
domestic rabbit monoclonal (4B5)
  • immunohistochemistry - paraffin section; human; loading ...; fig 6c
Ventana HER2 antibody (Ventana, 4B5) was used in immunohistochemistry - paraffin section on human samples (fig 6c). Oncotarget (2014) ncbi
BD Biosciences
mouse monoclonal (Neu 24.7)
  • flow cytometry; human; 1:50; loading ...; fig 2b, s14e
BD Biosciences HER2 antibody (BD Biosciences, 340552) was used in flow cytometry on human samples at 1:50 (fig 2b, s14e). Sci Transl Med (2021) ncbi
mouse monoclonal (3B5)
  • mass cytometry; human; loading ...; fig 3a
BD Biosciences HER2 antibody (BD Biosciences, 554299) was used in mass cytometry on human samples (fig 3a). Cell (2019) ncbi
mouse monoclonal (42/c-erbB-2)
  • western blot; human; loading ...; fig 3a
BD Biosciences HER2 antibody (BD, 610162) was used in western blot on human samples (fig 3a). Oncogene (2019) ncbi
mouse monoclonal (Neu 24.7)
  • flow cytometry; human; loading ...; fig 2a
BD Biosciences HER2 antibody (BD Biosciences, 340553) was used in flow cytometry on human samples (fig 2a). Cell Stress Chaperones (2017) ncbi
mouse monoclonal (Neu 24.7)
  • immunocytochemistry; human; 1:20; loading ...; fig 5c
BD Biosciences HER2 antibody (Becton Dickinson, 340554) was used in immunocytochemistry on human samples at 1:20 (fig 5c). J Clin Invest (2017) ncbi
mouse monoclonal (Neu 24.7)
  • flow cytometry; human; 1:133; loading ...; fig 4a
In order to suggest that EGFR promotes survival of prostate tumor-initiating cells and circulating tumor cells that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites, BD Biosciences HER2 antibody (B.D., Neu24.7) was used in flow cytometry on human samples at 1:133 (fig 4a). Cancer Res (2017) ncbi
mouse monoclonal (42/c-erbB-2)
  • western blot; human; loading ...; fig 3b
In order to determine the effect of a mixture of two monoclonal antibodies against non-overlapping epitopes of HER2 on HER2 stability and localization, BD Biosciences HER2 antibody (BD Biosciences, 42) was used in western blot on human samples (fig 3b). J Cell Mol Med (2016) ncbi
mouse monoclonal (Neu 24.7)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences HER2 antibody (BD, 340552) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (Neu 24.7)
  • flow cytometry; human; 1:50; fig 1
BD Biosciences HER2 antibody (BD Biosciences, 340552) was used in flow cytometry on human samples at 1:50 (fig 1). Cell Death Dis (2016) ncbi
mouse monoclonal (9G6)
  • other; human; loading ...; fig st1
In order to use size exclusion chromatography-microsphere-based affinity proteomics to study clinical samples obtained from pediatric acute leukemia patients, BD Biosciences HER2 antibody (BD, 9G6) was used in other on human samples (fig st1). Mol Cell Proteomics (2016) ncbi
mouse monoclonal (3B5)
  • immunocytochemistry; human; 1:100
  • western blot; human
BD Biosciences HER2 antibody (BD Transduction, 554299) was used in immunocytochemistry on human samples at 1:100 and in western blot on human samples . Clin Exp Metastasis (2015) ncbi
Leica Biosystems
mouse monoclonal (CB11)
  • immunohistochemistry - paraffin section; cat; loading ...; fig 1c
Leica Biosystems HER2 antibody (Novocastra, CB11) was used in immunohistochemistry - paraffin section on cat samples (fig 1c). Sci Rep (2020) ncbi
mouse monoclonal (CB11)
  • immunocytochemistry; human; 1:500; loading ...; fig s1
In order to investigate the use of altered double-strand break repair activities to classify breast cancers, Leica Biosystems HER2 antibody (Leica Biosystems, CB11) was used in immunocytochemistry on human samples at 1:500 (fig s1). FASEB J (2016) ncbi
mouse monoclonal (CB11)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 2
Leica Biosystems HER2 antibody (Novocastra Laboratories, NCL-CB11) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 2). Braz J Med Biol Res (2016) ncbi
monoclonal
  • immunohistochemistry; human; 1:50
In order to evaluate the potential protein markers of bone metastases in breast cancer patients, Leica Biosystems HER2 antibody (Novocastra, NCL-L-CB11) was used in immunohistochemistry on human samples at 1:50. Pathol Oncol Res (2015) ncbi
mouse monoclonal (CB11)
  • immunohistochemistry - paraffin section; human
Leica Biosystems HER2 antibody (Novocastra, NCL-CB11) was used in immunohistochemistry - paraffin section on human samples . J Clin Pathol (2015) ncbi
Articles Reviewed
  1. Feng K, Meng P, Zhang M, Zou X, Li S, Huang C, et al. IL-24 Contributes to Neutrophilic Asthma in an IL-17A-Dependent Manner and Is Suppressed by IL-37. Allergy Asthma Immunol Res. 2022;14:505-527 pubmed publisher
  2. Marei H, Tsai W, Kee Y, Ruiz K, He J, Cox C, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature. 2022;610:182-189 pubmed publisher
  3. Shu W, Zhu X, Wang K, Cherepanoff S, Conway R, Madigan M, et al. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma. Cell Oncol (Dordr). 2022;45:601-619 pubmed publisher
  4. Malanga D, Laudanna C, Mirante T, Colelli F, Migliozzi S, Zoppoli P, et al. The AKT1E17K Allele Promotes Breast Cancer in Mice. Cancers (Basel). 2022;14: pubmed publisher
  5. Wang Q, Bergholz J, Ding L, Lin Z, Kabraji S, Hughes M, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022;13:3022 pubmed publisher
  6. Eikmans M, van der Keur C, Anholts J, Drabbels J, van Beelen E, de Sousa Lopes S, et al. Primary Trophoblast Cultures: Characterization of HLA Profiles and Immune Cell Interactions. Front Immunol. 2022;13:814019 pubmed publisher
  7. Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, et al. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022;8:eabn3774 pubmed publisher
  8. Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y, et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac Cancer. 2022;13:1961-1973 pubmed publisher
  9. Due S, Watson D, Bastian I, Eichelmann A, Hussey D. Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma. Cancers (Basel). 2022;14: pubmed publisher
  10. Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13:1511 pubmed publisher
  11. Sarrio D, Rojo Sebasti xe1 n A, Teijo A, P xe9 rez L xf3 pez M, D xed az Mart xed n E, Mart xed nez L, et al. Gasdermin-B Pro-Tumor Function in Novel Knock-in Mouse Models Depends on the in vivo Biological Context. Front Cell Dev Biol. 2022;10:813929 pubmed publisher
  12. Dai J, Cimino P, Gouin K, Grzelak C, Barrett A, Lim A, et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Cancer. 2022;3:25-42 pubmed publisher
  13. Bajor M, Graczyk Jarzynka A, Marhelava K, Burdzińska A, Muchowicz A, Góral A, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022;10: pubmed publisher
  14. Humeres C, Shinde A, Hanna A, Alex L, Hern xe1 ndez S, Li R, et al. Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J Clin Invest. 2022;132: pubmed publisher
  15. Khasawneh R, Kist R, Queen R, Hussain R, Coxhead J, Schneider J, et al. Msx1 haploinsufficiency modifies the Pax9-deficient cardiovascular phenotype. BMC Dev Biol. 2021;21:14 pubmed publisher
  16. Goyette M, Elkholi I, Apcher C, Kuasne H, Rothlin C, Muller W, et al. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  17. Joh D, Heggestad J, Zhang S, Anderson G, Bhattacharyya J, Wardell S, et al. Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates. NPJ Breast Cancer. 2021;7:85 pubmed publisher
  18. Xie C, Ye F, Zhang N, Huang Y, Pan Y, Xie X. CCL7 contributes to angiotensin II-induced abdominal aortic aneurysm by promoting macrophage infiltration and pro-inflammatory phenotype. J Cell Mol Med. 2021;25:7280-7293 pubmed publisher
  19. Pham Q, Taniyama D, Sekino Y, Akabane S, Babasaki T, Kobayashi G, et al. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma. BMC Cancer. 2021;21:737 pubmed publisher
  20. Laine A, Nagelli S, Farrington C, Butt U, Cvrljevic A, Vainonen J, et al. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Res. 2021;81:4319-4331 pubmed publisher
  21. Zhu J, Cai T, Zhou J, Du W, Zeng Y, Liu T, et al. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer. J Exp Clin Cancer Res. 2021;40:192 pubmed publisher
  22. Wang J, Zhang Y, Xiao Y, Yuan X, Li P, Wang X, et al. Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. Am J Cancer Res. 2021;11:2005-2024 pubmed
  23. Kundumani Sridharan V, Subramani J, Owens C, Das K. Nrg1β Released in Remote Ischemic Preconditioning Improves Myocardial Perfusion and Decreases Ischemia/Reperfusion Injury via ErbB2-Mediated Rescue of Endothelial Nitric Oxide Synthase and Abrogation of Trx2 Autophagy. Arterioscler Thromb Vasc Biol. 2021;41:2293-2314 pubmed publisher
  24. Prokakis E, Dyas A, Grün R, Fritzsche S, Bedi U, Kazerouni Z, et al. USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response. Oncogene. 2021;40:4004-4018 pubmed publisher
  25. Bi Y, Chen X, Wei B, Wang L, Gong L, Li H, et al. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells. Theranostics. 2021;11:6355-6369 pubmed publisher
  26. Murray E, Cheng X, Krishna A, Jin X, Ohara T, Stappenbeck T, et al. HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium. Cell Mol Gastroenterol Hepatol. 2021;12:1105-1120 pubmed publisher
  27. Strobel S, Machiraju D, Hülsmeyer I, Becker J, Paschen A, Jager D, et al. Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. Life (Basel). 2021;11: pubmed publisher
  28. Chen Y, Wang R, Huang S, Henson E, Bi J, Gibson S. Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. Cancers (Basel). 2021;13: pubmed publisher
  29. Yang Y, Leonard M, Luo Z, Yeo S, Bick G, Hao M, et al. Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer. Cell Rep. 2021;34:108822 pubmed publisher
  30. Li W, Gu X, Liu C, Shi Y, Wang P, Zhang N, et al. A synergetic effect of BARD1 mutations on tumorigenesis. Nat Commun. 2021;12:1243 pubmed publisher
  31. Fu C, Zhang Q, Wang A, Yang S, Jiang Y, Bai L, et al. EWI-2 controls nucleocytoplasmic shuttling of EGFR signaling molecules and miRNA sorting in exosomes to inhibit prostate cancer cell metastasis. Mol Oncol. 2021;15:1543-1565 pubmed publisher
  32. Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, et al. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep. 2021;11:4165 pubmed publisher
  33. Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, et al. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med. 2021;13: pubmed publisher
  34. Isomura H, Taguchi A, Kajino T, Asai N, Nakatochi M, Kato S, et al. Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator. Cancer Sci. 2021;: pubmed publisher
  35. Le T, Galmiche L, Levy J, Suwannarat P, Hellebrekers D, Morarach K, et al. Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans. J Clin Invest. 2021;131: pubmed publisher
  36. Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed publisher
  37. Miller K, Pniewski K, Perry C, Papp S, Shaffer J, Velasco Silva J, et al. Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth. Cancer Res. 2021;81:1252-1264 pubmed publisher
  38. Zhang L, Gao Y, Zhang X, Guo M, Yang J, Cui H, et al. TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2. Theranostics. 2020;10:11339-11358 pubmed publisher
  39. Rogerson C, Ogden S, Britton E, Ang Y, Sharrocks A. Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma. elife. 2020;9: pubmed publisher
  40. Christgen M, Bartels S, van Luttikhuizen J, Bublitz J, Rieger L, Christgen H, et al. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Mod Pathol. 2020;33:2483-2498 pubmed publisher
  41. Choi B, Cha M, Eun G, Lee D, Lee S, Ehsan M, et al. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. elife. 2020;9: pubmed publisher
  42. Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, et al. A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma. BMC Cancer. 2020;20:154 pubmed publisher
  43. Hryciuk B, Pęksa R, Bieńkowski M, Szymanowski B, Radecka B, Winnik K, et al. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. Sci Rep. 2020;10:1871 pubmed publisher
  44. Biri Kovács B, Adorján A, Szabo I, Szeder B, Bosze S, Mezo G. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. Biomolecules. 2020;10: pubmed publisher
  45. Granados Soler J, Bornemann Kolatzki K, Beck J, Brenig B, Schütz E, Betz D, et al. Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival. Sci Rep. 2020;10:1003 pubmed publisher
  46. Liu Q, Borcherding N, Shao P, Maina P, Zhang W, Qi H. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance. EBioMedicine. 2020;51:102612 pubmed publisher
  47. Bueno M, Jimenez Renard V, Samino S, Capellades J, Junza A, López Rodríguez M, et al. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nat Commun. 2019;10:5011 pubmed publisher
  48. Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan Q, et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun Signal. 2019;17:109 pubmed publisher
  49. Nagpal A, Redvers R, Ling X, Ayton S, Fuentes M, Tavancheh E, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019;21:94 pubmed publisher
  50. Yin Y, Zhang Q, Zhao Q, Ding G, Wei C, Chang L, et al. Tongxinluo Attenuates Myocardiac Fibrosis after Acute Myocardial Infarction in Rats via Inhibition of Endothelial-to-Mesenchymal Transition. Biomed Res Int. 2019;2019:6595437 pubmed publisher
  51. Pietila M, Sahgal P, Peuhu E, Jäntti N, Paatero I, Närvä E, et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019;10:2340 pubmed publisher
  52. Chung H, Zou X, Bajar B, Brand V, Huo Y, Alcudia J, et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science. 2019;364: pubmed publisher
  53. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  54. Kennedy S, Han J, Portman N, Nobis M, Hastings J, Murphy K, et al. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Res. 2019;21:43 pubmed publisher
  55. Logtenberg M, Jansen J, Raaben M, Toebes M, Franke K, Brandsma A, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat Med. 2019;25:612-619 pubmed publisher
  56. Kaya P, Lee S, Lee Y, Kwon S, Yang H, Lee H, et al. Curcumae Radix Extract Decreases Mammary Tumor-Derived Lung Metastasis via Suppression of C-C Chemokine Receptor Type 7 Expression. Nutrients. 2019;11: pubmed publisher
  57. Greer Y, Gilbert S, Gril B, Narwal R, Peacock Brooks D, Tice D, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:27 pubmed publisher
  58. Keklikoglou I, Cianciaruso C, Güç E, Squadrito M, Spring L, Tazzyman S, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21:190-202 pubmed publisher
  59. Steele N, Chakrabarti J, Wang J, Biesiada J, Holokai L, Chang J, et al. An Organoid-Based Preclinical Model of Human Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2019;7:161-184 pubmed publisher
  60. Zhao H, Martin E, Matalkah F, Shah N, Ivanov A, Ruppert J, et al. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene. 2019;38:2275-2290 pubmed publisher
  61. Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed publisher
  62. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  63. Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, et al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. 2018;9:1024 pubmed publisher
  64. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926 pubmed publisher
  65. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed publisher
  66. Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman J. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281-72301 pubmed publisher
  67. Goel S, Decristo M, Watt A, BrinJones H, Sceneay J, Li B, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471-475 pubmed publisher
  68. Simond A, Rao T, Zuo D, Zhao J, Muller W. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene. 2017;36:6059-6066 pubmed publisher
  69. Doebar S, Sieuwerts A, de Weerd V, Stoop H, Martens J, van Deurzen C. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Am J Pathol. 2017;187:1648-1655 pubmed publisher
  70. Kwon S, Cho C, Kwon Y, Lee E, Park J. A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis. Sci Rep. 2017;7:45968 pubmed publisher
  71. Sinkala E, Sollier Christen E, Renier C, Rosàs Canyelles E, Che J, Heirich K, et al. Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun. 2017;8:14622 pubmed publisher
  72. Solis N, Swidergall M, Bruno V, Gaffen S, Filler S. The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio. 2017;8: pubmed publisher
  73. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher
  74. Lee S, Dempsey Hibbert N, Vimalachandran D, Wardle T, Sutton P, Williams J. Re-examining HSPC1 inhibitors. Cell Stress Chaperones. 2017;22:293-306 pubmed publisher
  75. Seberg H, Van Otterloo E, Loftus S, Liu H, Bonde G, Sompallae R, et al. TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF. PLoS Genet. 2017;13:e1006636 pubmed publisher
  76. Gomes de Castro M, Hobartner C, Opazo F. Aptamers provide superior stainings of cellular receptors studied under super-resolution microscopy. PLoS ONE. 2017;12:e0173050 pubmed publisher
  77. Schumacher M, Hedl M, Abraham C, Bernard J, Lozano P, Hsieh J, et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis. 2017;8:e2622 pubmed publisher
  78. Peiris D, Spector A, Lomax Browne H, Azimi T, Ramesh B, Loizidou M, et al. Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors. Sci Rep. 2017;7:43006 pubmed publisher
  79. Jin L, Chun J, Pan C, Alesi G, Li D, Magliocca K, et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene. 2017;36:3797-3806 pubmed publisher
  80. Radder J, Zhang Y, Gregory A, Yu S, Kelly N, Leader J, et al. Extreme Trait Whole-Genome Sequencing Identifies PTPRO as a Novel Candidate Gene in Emphysema with Severe Airflow Obstruction. Am J Respir Crit Care Med. 2017;196:159-171 pubmed publisher
  81. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher
  82. Qi L, Zhou L, Lu M, Yuan K, Li Z, Wu G, et al. Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips. Biochem Biophys Res Commun. 2017;484:248-254 pubmed publisher
  83. Andreev J, Thambi N, Perez Bay A, Delfino F, Martin J, Kelly M, et al. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16:681-693 pubmed publisher
  84. Hirai M, Arita Y, McGlade C, Lee K, Chen J, Evans S. Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest. 2017;127:569-582 pubmed publisher
  85. Hill S, Nesser N, Johnson Camacho K, Jeffress M, Johnson A, Boniface C, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst. 2017;4:73-83.e10 pubmed publisher
  86. Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, et al. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Sci Rep. 2016;6:39557 pubmed publisher
  87. Lloyd Lewis B, Davis F, Harris O, Hitchcock J, Lourenco F, Pasche M, et al. Imaging the mammary gland and mammary tumours in 3D: optical tissue clearing and immunofluorescence methods. Breast Cancer Res. 2016;18:127 pubmed
  88. Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed publisher
  89. Torgersen M, Klokk T, Kavaliauskiene S, Klose C, Simons K, Skotland T, et al. The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport. Oncotarget. 2016;7:86871-86888 pubmed publisher
  90. Sheen M, Marotti J, Allegrezza M, Rutkowski M, Conejo Garcia J, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5:e267 pubmed publisher
  91. Day K, Lorenzatti Hiles G, Kozminsky M, Dawsey S, Paul A, Broses L, et al. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res. 2017;77:74-85 pubmed publisher
  92. Parrales A, Ranjan A, Iyer S, Padhye S, Weir S, Roy A, et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016;18:1233-1243 pubmed publisher
  93. Shekhar A, Lin X, Liu F, Zhang J, Mo H, Bastarache L, et al. Transcription factor ETV1 is essential for rapid conduction in the heart. J Clin Invest. 2016;126:4444-4459 pubmed publisher
  94. Showler K, Nishimura M, Daino K, Imaoka T, Nishimura Y, Morioka T, et al. Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. J Radiat Res. 2017;58:183-194 pubmed publisher
  95. Mitra S, Ghosh B, Gayen N, Roy J, Mandal A. Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem. 2016;291:24579-24593 pubmed
  96. Kang S, Wang Y, Reder N, Liu J. Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry. PLoS ONE. 2016;11:e0163473 pubmed publisher
  97. Dobosz M, Haupt U, Scheuer W. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule. MAbs. 2017;9:140-153 pubmed publisher
  98. Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852 pubmed publisher
  99. Lee H, Noh H, Mun J, Gu C, Sever S, Park S. Anks1a regulates COPII-mediated anterograde transport of receptor tyrosine kinases critical for tumorigenesis. Nat Commun. 2016;7:12799 pubmed publisher
  100. Weitsman G, Barber P, Nguyen L, Lawler K, Patel G, Woodman N, et al. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget. 2016;7:51012-51026 pubmed publisher
  101. Nielsen T, Jensen M, Burugu S, Gao D, Jørgensen C, Balslev E, et al. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res. 2017;23:946-953 pubmed publisher
  102. Chung I, Reichelt M, Shao L, Akita R, Koeppen H, Rangell L, et al. High cell-surface density of HER2 deforms cell membranes. Nat Commun. 2016;7:12742 pubmed publisher
  103. Min L, Zhang C, Ma R, Li X, Yuan H, Li Y, et al. Overexpression of synuclein-? predicts lack of benefit from radiotherapy for breast cancer patients. BMC Cancer. 2016;16:717 pubmed publisher
  104. Jordan N, Bardia A, Wittner B, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537:102-106 pubmed publisher
  105. LAW M, Ferreira R, Davis B, Higgins P, Kim J, Castellano R, et al. CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res. 2016;18:80 pubmed publisher
  106. Deniz M, Kaufmann J, Stahl A, Gundelach T, Janni W, Hoffmann I, et al. In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis. FASEB J. 2016;30:3786-3799 pubmed
  107. Di Franco S, Turdo A, Benfante A, Colorito M, Gaggianesi M, Apuzzo T, et al. ?Np63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. Oncotarget. 2016;7:54157-54173 pubmed publisher
  108. Jiang Q, Chen S, Hu C, Huang P, Shen H, Zhao W. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Mol Med Rep. 2016;14:2614-24 pubmed publisher
  109. Szymanska M, Fosdahl A, Nikolaysen F, Pedersen M, Grandal M, Stang E, et al. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. J Cell Mol Med. 2016;20:1999-2011 pubmed publisher
  110. Merry C, McMahon S, Forrest M, Bartels C, Saiakhova A, Bartel C, et al. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. Oncotarget. 2016;7:53230-53244 pubmed publisher
  111. Liu Y, Wang K, Xing H, Zhai X, Wang L, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240-1256 pubmed
  112. Saisana M, Griffin S, May F. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget. 2016;7:54445-54462 pubmed publisher
  113. Deblois G, Smith H, Tam I, Gravel S, Caron M, Savage P, et al. ERR? mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun. 2016;7:12156 pubmed publisher
  114. Rowley M, Coolen A, Vojnovic B, Barber P. Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. PLoS ONE. 2016;11:e0158404 pubmed publisher
  115. Khan S, Sikander M, Ebeling M, Ganju A, Kumari S, Yallapu M, et al. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Oncogene. 2017;36:491-500 pubmed publisher
  116. Gray M, Lee S, McDowell A, Erskine M, Loh Q, Grice O, et al. Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro. Vet Comp Oncol. 2017;15:890-909 pubmed publisher
  117. Sochaj Gregorczyk A, Serwotka Suszczak A, Otlewski J. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines. J Immunother. 2016;39:223-32 pubmed publisher
  118. Leo F, Bartels S, Mägel L, Framke T, Büsche G, Jonigk D, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch. 2016;469:191-201 pubmed publisher
  119. Yang Z, Jiang Q, Chen S, Hu C, Shen H, Huang P, et al. Differential changes in Neuregulin-1 signaling in major brain regions in a lipopolysaccharide-induced neuroinflammation mouse model. Mol Med Rep. 2016;14:790-6 pubmed publisher
  120. Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher
  121. Hsieh M, Yang P, Wong L, Lee J. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget. 2016;7:36956-36970 pubmed publisher
  122. de Geus S, Boogerd L, Swijnenburg R, Mieog J, Tummers W, Prevoo H, et al. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Mol Imaging Biol. 2016;18:807-819 pubmed
  123. Song M, Park Y, Song H, Park S, Ahn J, Choi K, et al. Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study. Gut Liver. 2016;10:731-8 pubmed publisher
  124. Yard B, Adams D, Chie E, Tamayo P, Battaglia J, Gopal P, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7:11428 pubmed publisher
  125. Belov L, Matic K, Hallal S, Best O, Mulligan S, Christopherson R. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles. 2016;5:25355 pubmed publisher
  126. Marcus E, Tokhtaeva E, Turdikulova S, Capri J, Whitelegge J, Scott D, et al. Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells. Biochem J. 2016;473:1703-18 pubmed publisher
  127. Papadakis E, Barker C, Syed H, Reeves T, Schwaiger S, Stuppner H, et al. The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Oncogenesis. 2016;5:e215 pubmed publisher
  128. Gschweitl M, Ulbricht A, Barnes C, Enchev R, Stoffel Studer I, Meyer Schaller N, et al. A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes. elife. 2016;5:e13841 pubmed publisher
  129. Ongaratti B, Silva C, Trott G, Haag T, Leães C, Ferreira N, et al. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res. 2016;49:e5125 pubmed publisher
  130. Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed publisher
  131. Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher
  132. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  133. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
  134. Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed publisher
  135. Choi W, de Poot S, Lee J, Kim J, Han D, Kim Y, et al. Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. Nat Commun. 2016;7:10963 pubmed publisher
  136. Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher
  137. Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed publisher
  138. Wang Y, Kang S, Khan A, Ruttner G, Leigh S, Murray M, et al. Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy. Sci Rep. 2016;6:21242 pubmed publisher
  139. Kim D, Helfman D. Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene. 2016;35:4495-508 pubmed publisher
  140. Dupouy D, Ciftlik A, Fiche M, Heintze D, Bisig B, de Leval L, et al. Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer. Sci Rep. 2016;6:20277 pubmed publisher
  141. Evans M, Sauer S, Nath S, Robinson T, Morse M, Devi G. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016;7:e2073 pubmed publisher
  142. Teng Y, Pi W, Wang Y, Cowell J. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling. Oncogene. 2016;35:4633-40 pubmed publisher
  143. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed publisher
  144. Roßner F, Gieseler C, Morkel M, Royer H, Rivera M, Bläker H, et al. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis. 2016;5:e187 pubmed publisher
  145. Khalil H, Langdon S, Kankia I, Bown J, Deeni Y. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016;2016:4148791 pubmed publisher
  146. Nalwoga H, Ahmed L, Arnes J, Wabinga H, Akslen L. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS ONE. 2016;11:e0146823 pubmed publisher
  147. Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
  148. Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun. 2016;7:10060 pubmed publisher
  149. Creedon H, Balderstone L, Muir M, Balla J, Gómez Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed publisher
  150. Siegfried J, Lin Y, Diergaarde B, Lin H, Dacic S, Pennathur A, et al. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia. 2015;17:817-25 pubmed publisher
  151. Vishnoi M, Peddibhotla S, Yin W, T Scamardo A, George G, Hong D, et al. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep. 2015;5:17533 pubmed publisher
  152. El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed publisher
  153. Chen J, Chen Y, Yen C, Chen W, Huang W. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016;7:473-89 pubmed publisher
  154. Clemente Vicario F, Alvarez C, ROWELL J, Roy S, London C, Kisseberth W, et al. Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. PLoS ONE. 2015;10:e0142007 pubmed publisher
  155. Askoxylakis V, Ferraro G, Kodack D, Badeaux M, Shankaraiah R, Seano G, et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst. 2016;108: pubmed publisher
  156. Pai P, Rachagani S, Lakshmanan I, Macha M, Sheinin Y, Smith L, et al. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Mol Oncol. 2016;10:224-39 pubmed publisher
  157. Prince T, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, et al. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants. PLoS ONE. 2015;10:e0141786 pubmed publisher
  158. Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15:726 pubmed publisher
  159. Rodríguez C, Reidel S, Bal de Kier Joffé E, Jasnis M, Fiszman G. Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids. PLoS ONE. 2015;10:e0137920 pubmed publisher
  160. Wu Y, Deng W, Klinke D. Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers. Analyst. 2015;140:6631-42 pubmed publisher
  161. Gómez R, Ossa C, Montoya M, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562 pubmed publisher
  162. KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher
  163. Capparelli C, Rosenbaum S, Berger A, Aplin A. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 2015;290:24267-77 pubmed publisher
  164. Wang D, Pang Z, Clarke G, Nofech Mozes S, Liu K, Cheung A, et al. Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining. Appl Immunohistochem Mol Morphol. 2016;24:447-52 pubmed publisher
  165. Leung K, Batey S, Rowlands R, Isaac S, Jones P, Drewett V, et al. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Mol Ther. 2015;23:1722-1733 pubmed publisher
  166. Abdel Latif G, Al Abd A, Tadros M, Al Abbasi F, Khalifa A, Abdel Naim A. The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Sci Rep. 2015;5:12054 pubmed publisher
  167. Hagrass H, Sharaf S, Pasha H, Tantawy E, Mohamed R, Kassem R. Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer. 2015;6:281-7 pubmed
  168. Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed publisher
  169. Blancafort A, Giró Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher
  170. Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed
  171. Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed
  172. Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed publisher
  173. Winczura P, Sosińska Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, et al. Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients. Pathol Oncol Res. 2015;21:1229-36 pubmed publisher
  174. Kurppa K, Denessiouk K, Johnson M, Elenius K. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene. 2016;35:1283-91 pubmed publisher
  175. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
  176. Hofmann B, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 2015;14:109 pubmed publisher
  177. de Deus Moura R, Carvalho F, Bacchi C. Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast. 2015;24:461-7 pubmed publisher
  178. Demicco E, Wani K, Fox P, Bassett R, Young E, Lev D, et al. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol. 2015;46:1015-26 pubmed publisher
  179. Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncol Rep. 2015;34:504-10 pubmed publisher
  180. Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed publisher
  181. UgraÅŸ N, Özgün G, OcakoÄŸlu G, Yerci Ã, Öztürk E. Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?. Turk J Gastroenterol. 2014;25 Suppl 1:176-81 pubmed publisher
  182. Liu H, Du L, Wang R, Wei C, Liu B, Zhu L, et al. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy. Oncotarget. 2015;6:11477-91 pubmed
  183. Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z, et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol. 2015;33:1951-7 pubmed publisher
  184. Yardley D, Kaufman P, Huang W, Krekow L, Savin M, Lawler W, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Res. 2015;17:41 pubmed publisher
  185. Deleyrolle L, Sabourin J, Rothhut B, Fujita H, Guichet P, Teigell M, et al. OCAM regulates embryonic spinal cord stem cell proliferation by modulating ErbB2 receptor. PLoS ONE. 2015;10:e0122337 pubmed publisher
  186. Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed
  187. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  188. Savci Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57 pubmed publisher
  189. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol. 2015;45:416-21 pubmed publisher
  190. Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed publisher
  191. Cuello Carrión F, Shortrede J, Alvarez Olmedo D, Cayado Gutiérrez N, Castro G, Zoppino F, et al. HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations. Clin Exp Metastasis. 2015;32:151-68 pubmed publisher
  192. Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget. 2015;6:1695-706 pubmed
  193. Tökés A, Szász A, Geszti F, Lukács L, Kenessey I, Turányi E, et al. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol. 2015;68:274-82 pubmed publisher
  194. Yoo J, Kim T, Kong S, Lee J, Choi W, Kim K, et al. Role of Mig-6 in hepatic glucose metabolism. J Diabetes. 2016;8:86-97 pubmed publisher
  195. Blanchard Z, Paul B, Craft B, ElShamy W. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res. 2015;17:5 pubmed publisher
  196. Kumar S, Das S, Rachagani S, Kaur S, Joshi S, Johansson S, et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene. 2015;34:4879-89 pubmed publisher
  197. Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9:17-24 pubmed
  198. Katz Y, Li F, Lambert N, Sokol E, Tam W, Cheng A, et al. Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state. elife. 2014;3:e03915 pubmed publisher
  199. Hong Y, Kim J, Pectasides E, Fox C, Hong S, Ma Q, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS ONE. 2014;9:e109440 pubmed publisher
  200. Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, et al. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5:7138-48 pubmed
  201. Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed publisher
  202. Mahajan K, Lawrence H, Lawrence N, Mahajan N. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem. 2014;289:28179-91 pubmed publisher
  203. Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher
  204. Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
  205. Zeng L, Holly J, Perks C. Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol (Lausanne). 2014;5:61 pubmed publisher
  206. Jung S, Ohk J, Jeong D, Li C, Lee S, Duan J, et al. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells. Int J Oncol. 2014;45:189-96 pubmed publisher
  207. Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta. 2014;1843:1987-96 pubmed publisher
  208. Jakob J, Kies M, Glisson B, Kupferman M, Liu D, Lee J, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37:644-9 pubmed publisher
  209. Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol. 2014;16:1196-209 pubmed publisher
  210. Neumeister V, Parisi F, England A, Siddiqui S, Anagnostou V, Zarrella E, et al. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Lab Invest. 2014;94:467-74 pubmed publisher
  211. Jackson D, Atkinson J, Guevara C, Zhang C, Kery V, Moon S, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE. 2014;9:e83865 pubmed publisher
  212. Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W. The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition. Int J Oncol. 2014;44:735-44 pubmed publisher
  213. Xu C, Chen H, Wang X, Gao J, Che Y, Li Y, et al. S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem. 2014;289:827-37 pubmed publisher
  214. Wakatsuki S, Araki T, Sehara Fujisawa A. Neuregulin-1/glial growth factor stimulates Schwann cell migration by inducing ?5 ?1 integrin-ErbB2-focal adhesion kinase complex formation. Genes Cells. 2014;19:66-77 pubmed publisher
  215. Qiu S, Wei X, Huang W, Wu M, Qin Y, Li Y, et al. Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma. Sci Rep. 2013;3:2529 pubmed publisher
  216. Vlug E, van de Ven R, Vermeulen J, Bult P, van Diest P, Derksen P. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 2013;36:375-84 pubmed publisher
  217. Aguiar F, Mendes H, Cirqueira C, Bacchi C, Carvalho F. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. Clinics (Sao Paulo). 2013;68:638-43 pubmed publisher
  218. Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher
  219. Sak M, Szymanska M, Bertelsen V, Hasmann M, Madshus I, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis. 2013;34:2031-8 pubmed publisher
  220. Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med. 2013;17:116-22 pubmed publisher
  221. Harmelink C, Peng Y, Debenedittis P, Chen H, Shou W, Jiao K. Myocardial Mycn is essential for mouse ventricular wall morphogenesis. Dev Biol. 2013;373:53-63 pubmed publisher
  222. Cadenas C, Vosbeck S, Hein E, Hellwig B, Langer A, Hayen H, et al. Glycerophospholipid profile in oncogene-induced senescence. Biochim Biophys Acta. 2012;1821:1256-68 pubmed publisher
  223. Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher
  224. Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed publisher
  225. Wang H, Leavitt L, Ramaswamy R, Rapraeger A. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J Biol Chem. 2010;285:13569-79 pubmed publisher
  226. Kim T, Huh J, Lee S, Kang H, Kim G, An H. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology. 2008;53:48-55 pubmed publisher
  227. Najy A, Day K, Day M. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283:18393-401 pubmed publisher
  228. Lerdrup M, Hommelgaard A, Grandal M, van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci. 2006;119:85-95 pubmed
  229. Traxler P, Allegrini P, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-41 pubmed